REGENXBIO(US:RGNX) Globenewswire·2026-02-17 19:44Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against REGENXBIO Inc. due to allegations of violations of federal securities laws related to misleading statements about the efficacy and safety of its RGX-111 trial study [4][5]. Group 1: Legal Investigation - The firm is reminding investors of the April 14, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against REGENXBIO [4]. - The investigation follows a press release from REGENXBIO on January 28, 2026, announcing a clinical hold by the FDA on its RGX-111 investigational gene therapy due to a case of neoplasm in a trial participant [6]. - Following the announcement, REGENXBIO's stock price dropped by $2.40 per share, or 17.9%, closing at $11.01 per share [6]. Group 2: Company Background - REGENXBIO is involved in gene therapy, specifically targeting conditions such as MPS I (Hurler syndrome) and MPS II (Hunter syndrome) [6]. - The firm has recovered hundreds of millions of dollars for investors since its founding in 1995, indicating a strong track record in securities law [5].